Strikingly, in KRAS-driven NSCLC, a common phenomenon is co-mutations in tumor suppressor genes (TSGs), which orchestrate resistance through multifaceted pathways such as sustained proliferation, metabolic reprogramming, phenotypic plasticity, and immune microenvironment remodeling. This evidence concerns the gene KRAS and non-small cell lung carcinoma.